A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction
| Autor: | Werner Jung, Gerhard Lauck, Marcus Reuter, Hegder Omran, Matthias Manz |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Ejection fraction Heart disease business.industry medicine.medical_treatment Cardiomyopathy Stroke volume Antiarrhythmic agent medicine.disease Coronary artery disease Internal medicine Anesthesia Heart rate medicine Cardiology Pharmacology (medical) Cardiology and Cardiovascular Medicine business Ivabradine medicine.drug |
| Zdroj: | Cardiology. 100:149-155 |
| ISSN: | 1421-9751 0008-6312 |
| DOI: | 10.1159/000073933 |
| Popis: | This randomized, single-blind, placebo-controlled study investigated the effect of ivabradine, a novel heart rate-lowering agent, on echocardiographic indices of left ventricular (LV) systolic function in patients with regional (coronary artery disease) or global (cardiomyopathy) LV dysfunction. Patients were randomized on an unequal basis to receive ivabradine 0.25 mg/kg (n = 31) or placebo (n = 13) by intravenous infusion. Resting heart rate was reduced by a mean of 17.6 ± 4.7% with ivabradine and 1.5 ± 5.8% with placebo. The mean maximum decrease in LV ejection fraction was 0.2% with ivabradine and 1.7% with placebo. Fractional shortening and stroke volume were also fully preserved after ivabradine administration. Thus, a single intravenous dose of ivabradine produced a substantial reduction in resting heart rate without affecting LV function in patients with regional or global LV dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|